MASLD rates have decreased, whereas liver fibrosis and cirrhosis rates have increased among US patients with type 2 diabetes since 2017.

The fluorescent labeling compound—dubbed "Sialyl Lewis Yellow"—was developed by an international team led from the Pohang University of Science and Technology in South Korea. It works by binding to ...

Objectives Elevated liver enzyme concentrations in blood are indicative of liver diseases and may provide an early signal for being at risk for other chronic diseases. Our study aimed to assess the ...

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center may help explain why certain liver ...

Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

A research team led by Prof. Hai Li from the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has become the first to systematically explore how large language models (LLMs) can ...

Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...

Liu et al. (20) indicate that combined treatment with DEB-TACE has advantages in improving the prognosis of early-stage liver cancer compared to MWA alone. However, few studies have focused on the ...